FGF23 and Fabry disease: Previous efforts have been done to characterize released factors in FD other than RANKL/OPG, including the demonstration of lesional FGF23 excess(10) and the investigation of IL6 in this disease, that led to the unsuccessful attempt to treat FD patients with the IL6R-inhibiting drug tocilizumab(11–13).